Other Events ·
LeonaBio, Inc. announced the enrollment of the 500th subject in its Phase 3 ELAINE-3 clinical trial for lasofoxifene…
ATHAAthira Pharma, Inc.
LeonaBio, Inc. announced the enrollment of the 500th subject in its Phase 3 ELAINE-3 clinical trial for lasofoxifene combined with abemaciclib to treat ER+, HER2-negative, ESR1-mutated metastatic breast cancer. This event triggers the initial exercise date for 23,031,494 Series A Common Warrants issued in a December 2025 private placement. These warrants carry a $6.35 per share cash exercise price and expire no later than November 30, 2026. Full exercise would generate approximately $146.2 million in additional capital for the company. LeonaBio operates as a clinical-stage biotechnology company focused on developing targeted therapies for breast cancer.